Bausch Health(BHC) ZACKS·2025-02-17 15:20Core Viewpoint - Analysts project that Bausch Health (BHC) will report quarterly earnings of $1.12 per share, reflecting a year-over-year decline of 2.6%, while revenues are expected to reach $2.51 billion, an increase of 4.3% from the same quarter last year [1]. Earnings Projections - Over the last 30 days, the consensus EPS estimate for the quarter has been revised upward by 0.8%, indicating a collective reassessment by covering analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Revenue Estimates - Total Bausch + Lomb revenues are estimated at $1.23 billion, representing a year-over-year increase of 4.8% [5]. - Revenues from Diversified Products are projected to be $252.98 million, indicating a decline of 2.3% year over year [5]. - Total Bausch Health revenues (excluding B+L) are expected to reach $1.26 billion, reflecting a year-over-year increase of 2.1% [5]. Segment-Specific Revenue Forecasts - Revenues from Salix are forecasted at $598.47 million, showing a year-over-year increase of 2.7% [6]. - Solta Medical revenues are expected to be $115.36 million, indicating a 12% increase from the prior year [6]. - International revenues are projected to reach $294.30 million, reflecting a year-over-year increase of 1.5% [6]. Bausch + Lomb Product Revenues - Vision Care revenues are expected to be $698.94 million, indicating a year-over-year increase of 5.6% [7]. - Surgical revenues are projected at $213.60 million, reflecting a 4.7% increase year over year [7]. - Revenues from Diversified Products in Ortho Dermatology are expected to be $59.93 million, indicating a decline of 1.8% year over year [7]. Additional Product Revenue Estimates - Revenues from Diversified Products in Dentistry are projected at $23.49 million, reflecting a significant decline of 19% from the prior year [8]. - Revenues from Diversified Products in Generics are expected to be $17.13 million, indicating a substantial decline of 38.8% year over year [8]. - Neuro-related revenues are estimated at $159.79 million, reflecting a year-over-year increase of 13.3% [9]. Stock Performance - Over the past month, Bausch shares have declined by 17.2%, contrasting with the Zacks S&P 500 composite's increase of 4.7% [9].